Personalized and Adaptive Breast Cancer Treatment System
Legal Citation
Summary of the Inventive Concept
A next-generation breast cancer treatment system that leverages machine learning, gene editing, and real-time monitoring to provide personalized and adaptive therapy, overcoming the limitations of traditional treatments.
Background and Problem Solved
The original patent disclosed a nanomedicinal composition for treating breast cancer, but it had limitations in terms of personalized treatment and real-time adaptation. The new inventive concept addresses these limitations by integrating machine learning, gene editing, and real-time monitoring to provide a more effective and targeted treatment approach.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for personalized breast cancer treatment, which includes a nanocarrier with a porous silicate matrix and particles of a magnetic ferrite, a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant, and a machine learning algorithm configured to optimize the pharmaceutical agent mixture based on the subject's genetic profile. The system can also adjust the pharmaceutical composition in real-time based on the subject's response to treatment. Additionally, the system can be integrated with gene editing tools and miniature electromagnetic coils for targeted and in-situ treatment. The system's real-time monitoring capabilities enable early detection of breast cancer and prevention of the disease.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious features, including the integration of machine learning and gene editing tools, real-time monitoring and adaptation, and in-situ treatment capabilities. These features overcome the limitations of traditional breast cancer treatments and provide a more effective and targeted approach.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different types of nanoparticles or gene editing tools, or integrating the system with other diagnostic or therapeutic modalities. Variations of the system could also be developed for treating other types of cancer or diseases.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the field of personalized medicine and cancer treatment. The system could be marketed to hospitals, clinics, and research institutions, and could also be used in conjunction with other diagnostic or therapeutic modalities. The market potential is significant, with the global cancer treatment market projected to reach $150 billion by 2025.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6923 |
| A | A61 | A61K31/138 |
| A | A61 | A61K31/282 |
| A | A61 | A61K33/243 |
| A | A61 | A61K47/10 |
| A | A61 | A61K2121/00 |
| A | A61 | A61K2800/47 |
| B | B82 | B82Y5/00 |
| B | B82 | B82Y25/00 |
| B | B82 | B82Y30/00 |
| B | B82 | B82Y40/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Nanomedicine, cancer therapeutics, and targeted drug delivery systems, with expertise in nanocarrier design, pharmaceutical composition optimization, and personalized medical treatment strategies
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in biomedical engineering, nanotechnology, or pharmaceutical sciences, possessing knowledge of nanoparticle synthesis, drug delivery mechanisms, and computational modeling techniques
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's integration of machine learning, real-time monitoring, and gene editing tools represents predictable extensions of existing nanomedicinal cancer treatment approaches. The core nanocarrier technology remains substantially similar to the source patent, with the primary innovations being algorithmic and adaptive treatment strategies. These variations would be considered obvious improvements leveraging known computational and biotechnological techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,639 |
|---|---|
| Title | Method for treating breast cancer |
| Assignee(s) | Imam Abdulrahman Bin Faisal University |